GlassScriptPhysician profile
Sandeep Bansal
NPI 1861586133
$100,456.08
in general payments reported to CMS, 2019-2025
23 companies · $18K in 2025
The $18K reported for 2025 was more than what 88% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $3,778 · 2021: $9,783 · 2022: $19K · 2023: $17K · 2024: $16K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Travel and Lodging: $14K · Consulting Fee: $12K · Food and Beverage: $8,092 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,820.00 |
| Travel and Lodging | $14,163.51 |
| Consulting Fee | $11,776.83 |
| Food and Beverage | $8,091.80 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $40,371.23 | 2021-2025 | Evera Mri Xt Dr Surescan, Selectsecure, Aurora Ev-Icd Mri Surescan |
| Merit Medical Systems INC | $17,940.32 | 2019-2025 | Prelude Introducers |
| Biosense Webster, INC. | $14,425.74 | 2019-2025 | Carto 3, Nuvision Ice Catheter |
| Abbott Laboratories | $12,987.03 | 2019-2025 | Aveir, Tendril, Confirm Rx |
| Medical Device Business Services, INC. | $4,537.48 | 2019-2024 | Carto 3 |
| Boston Scientific Corporation | $3,933.32 | 2019-2025 | Watchman Flx, Farapulse, General - Ep |
| Impulse Dynamics (USA) INC. | $3,000.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $1,743.68 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $439.72 | 2023-2024 | Breztri |
| Medtronic Vascular, INC. | $321.98 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $137.50 | 2023 | Opsumit, Uptravi |
| Viatris Specialty LLC | $124.99 | 2025 | Yupelri |
| Regeneron Pharmaceuticals, INC. | $102.19 | 2022-2023 | Dupixent |
| Biotronik INC. | $97.18 | 2023 | Biomonitor |
| Sanofi-Aventis U.S. LLC | $84.99 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $48.24 | 2025 | Ohtuvayre |
| Glaxosmithkline, LLC. | $48.02 | 2022 | |
| Abiomed | $38.27 | 2020-2022 | |
| Novo Nordisk INC | $20.62 | 2025 | Wegovy |
| Pulmonx Corporation | $19.80 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Teleflex LLC | $18.46 | 2025 | Guideliner |
| Electromed, INC. | $15.32 | 2023 | Smartvest |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Bansal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.